XML 51 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Stock-Based Compensation
9 Months Ended
Sep. 29, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
Note 12. Stock-Based Compensation
The fair value of each option award is estimated on the date of grant using the Black-Scholes valuation model and the assumptions noted in the following table. The expected term of options granted was calculated using the simplified method. The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. The expected volatility is based on the historical volatility of Nanometrics’ stock price. The dividend yield reflects that the Company has not paid any     cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future.
 
Three Months Ended
 
Nine Months Ended
 
September 29,
2012
 
October 1,
2011
 
September 29,
2012
 
October 1,
2011
Stock Options
 
 
 
 
 
 
 
Expected life
4.6 years

 
4.6 years

 
4.5 years

 
4.5 years

Volatility
75.44
%
 
77.47
%
 
77.96
%
 
77.02
%
Risk free interest rate
0.74
%
 
1.01
%
 
0.84
%
 
1.89
%
Dividends

 

 

 

Employee Stock Purchase Plan
 
 
 
 
 
 
 
Expected life
0.5 years

 
0.5 years

 
0.5 years

 
0.5 years

Volatility
38.58
%
 
65.91
%
 
45.47
%
 
73.41
%
Risk free interest rate
0.16
%
 
0.17
%
 
0.12
%
 
0.19
%
Dividends

 

 

 


The weighted average fair value per share of the stock options awarded in the three month and nine month periods ended September 29, 2012 was $8.94 and $10.50, respectively, based on the fair market value of the Company’s common stock on the grant dates. The weighted average fair value per share of the stock options awarded in the three month and nine month periods ended October 1, 2011 was $9.71 and $9.95, respectively, based on the fair market value of the Company’s common stock on the grant dates.
A summary of activity under the Company’s stock option plans during the nine month period ended September 29, 2012 is as follows:
 
 
Number of
Shares
Outstanding
(Options)
 
Weighted
Average
Exercise
Price
 
Weighted
Average
Remaining
Contractual Term (Years)
 
Aggregate Intrinsic Value (in Thousands)
Options
 
 
 
 
 
 
 
Outstanding at December 31, 2011
2,348,162

 
$
10.53

 
4.86

 
$
18,556

Exercised
(403,397
)
 
6.47

 
 
 
 
Granted
221,785

 
17.48

 
 
 
 
Cancelled
(112,087
)
 
14.72

 
 
 
 
Outstanding at September 29, 2012
2,054,463

 
$
11.85

 
4.53

 
$
6,642

Exercisable at September 29, 2012
1,206,804

 
$
9.68

 
3.83

 
$
5,811


The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on the Company’s closing stock price of $13.81 as of September 29, 2012 which would have been received by the option holders had all option holders exercised their options as of that date. The total intrinsic value of options exercised during the three month and nine month periods ended September 29, 2012 was $1.0 million and $4.5 million, respectively. The total intrinsic value of options exercised during the three month and nine month periods ended October 1, 2011 was $1.3 million and $8.2 million, respectively.
During the nine month period ended September 29, 2012, 18,534 Restricted Stock Units (“RSUs”) were released, and the Company granted 51,777 RSUs which vest between three and four years after the vesting commencement date identified in the applicable grant document. As of September 29, 2012, there were 333,301 RSUs outstanding.
Stock-based compensation expense for all share-based payment awards made to the Company’s employees and directors pursuant to the employee stock option and employee stock purchase plans by function were as follows (in thousands):
 
 
Three Months Ended
 
Nine Months Ended
 
September 29,
2012

October 1,
2011
 
September 29,
2012

October 1,
2011
Cost of products
$
50

 
$
45

 
$
128

 
$
111

Cost of service
62

 
51

 
195

 
146

Research and development
289

 
221

 
952

 
589

Selling
451

 
264

 
1,374

 
790

General and administrative
630

 
389

 
1,886

 
1,110

Total stock-based compensation expense
$
1,482

 
$
970

 
$
4,535

 
$
2,746